Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
8.16 ^USD	-3.77%		-22.21%	+14.45%

May. 02	Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 04	Shattuck Labs, Inc. Announces Board Appointments	CI

Shattuck Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 08, 2022 at 04:32 pm EST

Shattuck Labs, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 24.64 million compared to USD 17.41 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.41 a year ago.
For the nine months, net loss was USD 76.53 million compared to USD 52.82 million a year ago. Basic loss per share from continuing operations was USD 1.81 compared to USD 1.26 a year ago.

Latest news about Shattuck Labs, Inc.

Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Shattuck Labs, Inc. Announces Board Appointments	Mar. 04	CI
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Mar. 01	MT
Shattuck Labs Shares Rise as Q4 Net Loss Narrows	Mar. 01	MT
Shattuck Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Shattuck Labs, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14	MT
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma	Feb. 13	DJ
Shattuck Labs, Inc. Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	CI
Shattuck Labs Insider Sold Shares Worth $250,000, According to a Recent SEC Filing	Jan. 16	MT
Transcript : Shattuck Labs, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
Shattuck Labs, Inc. Files Initial Topline Dose-Exp Expansion Data from Its Ongoing Phase 1A/B Clinical Trial of Sl-172154 in Frontline Tp53m Aml and Tp53m Aml Patients	Dec. 21	CI
Shattuck Labs, Inc. announced that it expects to receive $19.999998 million in funding	Dec. 20	CI
Shattuck Labs Shares Soar as Blood Cancer Therapy Trial Yields 79% Objective Response Rate	Dec. 13	MT
Top Midday Gainers	Dec. 13	MT
Fed Meeting Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Wednesday	Dec. 13	MT
Top Premarket Gainers	Dec. 13	MT
Transcript : Shattuck Labs, Inc. - Special Call	Dec. 13
Transcript : Shattuck Labs, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Shattuck Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia and Higher-Mds) Patients At the American Society of Hematology 2023 Annual Meeting	Nov. 02	CI
Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from S&P Global BMI Index	23-09-18	CI
Berenberg Bank Adjusts Shattuck Labs Price Target to $4 From $20, Maintains Buy Rating	23-09-15	MT
Needham Adjusts Shattuck Labs' Price Target to $12 From $14, Keeps Buy Rating	23-08-11	MT

Chart Shattuck Labs, Inc.

Duration

Period

More charts

Company Profile

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Shattuck Labs, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.16 USD

Average target price

15.75 USD

Spread / Average Target

+93.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SHATTUCK LABS, INC.	+14.45%	403M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research